- Home
- PHAR vs GHRS Comparison
PHAR vs GHRS Comparison
Compare PHAR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | GHRS |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | Netherlands | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHAR | GHRS |
|---|---|---|
| Price | $18.36 | $17.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $38.33 | ★ $41.38 |
| AVG Volume (30 Days) | 12.9K | ★ 116.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.05 | $8.66 |
| 52 Week High | $21.34 | $19.51 |
Technical Indicators
Market Signals| Indicator | PHAR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 68.13 |
| Support Level | $16.90 | $12.34 |
| Resistance Level | $17.70 | $19.26 |
| Average True Range (ATR) | 0.64 | 0.86 |
| MACD | 0.14 | 0.38 |
| Stochastic Oscillator | 61.10 | 85.89 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.